Utility of Immunofluorescence in the Diagnosis of Glomerulopathies


Introduction: Glomerulopathies constitute aheterogeneous group of diseases that are difficult to diagnose and immunofluorescence is currently considered an invaluable technique to establish an adequate diagnosis and a correct therapeutic approach. Objective: To contribute to the updating of the scientific community in relation to the diagnosis of this pathology with the use of immunofluorescence. Methodology: A non-systematic bibliographic review was carried out in the databases available on the Internet such as: Scielo, Elsevier, Cochrane Library, PubMed, Intramed. This search was conducted in both Spanish and English. Results: 55 bibliographic sources were found, of which 30 relevant scientific articles were used and 25 were excluded because they did not meet the selection criteria. Discussion: Glomerulopathies comprise a group of diseases that affect renal function, they can be primary or secondary and have an acute or chronic and progressive course, with high morbidity and mortality worldwide, since they can lead patients to renal failure, Therefore, the use of diagnostic means such as immunofluorescence is an invaluable tool to achieve a specific diagnosis, which will result in an appropriate therapeutic approach for each patient. Conclusion: Immunofluorescence is an invaluable technique in the diagnosis of glomerulopathies that facilitates an adequate therapeutic approach for patients. And it allows to establish the specific type between the different variants of this group of diseases.

Keywords: glomerulopathies, immunofluorescence, renal failure, glomerular filtration, immune complex deposits.


Introducción: Las glomerulopatías constituyen un grupo heterogéneo de enfermedades de difícil diagnóstico y la inmunofluorescencia es considerada en la actualidad una técnica de inestimable valor para establecer un diagnóstico adecuado y un correcto enfoque terapéutico. Objetivo: Contribuir a la actualización de la comunidad científica en relación al diagnóstico de esta patología con el uso de la inmunofluorescencia. Métodos: Se realizó una revisión bibliográfica no sistemática en las bases de datos disponibles de internet como: Scielo, Elsevier, Biblioteca Cochrane, PubMed, Intramed. Esta búsqueda se realizó tanto en español como en inglés. Resultados: Se encontraron 55 fuentes bibliográficas, de las cuales se utilizaron 30 artículos científicos de relevancia y se excluyeron 25 debido a que no llegaron a cumplir con los criterios de selección. Discusión: Las glomerulopatías comprenden un grupo de enfermedades que afectan la función renal, pueden ser primarias o secundarias y tener un curso agudo o crónico y progresivo, con una alta morbimortalidad a nivel mundial, ya que pueden llevar a los pacientes a la insuficiencia renal, por lo que el uso de los medios diagnósticos como la inmunofluorescencia es de gran utilidad para definir el tipo específico dentro de este grupo heterogéneo de dolencias, lo que redundará en una mayor calidad de la asistencia médica para cada paciente. Conclusiones: La inmunofluorescencia es una técnica de valor inestimable en el diagnóstico de las glomerulopatías que facilita un enfoque terapéutico adecuado para los pacientes. Y permite establecer el tipo específico entre las diferentes variantes de este grupo de enfermedades.

Palabras clave: glomerulopatías, inmunofluorescencia, insuficiencia renal, filtrado glomerular, depósitos de inmunocomplejos.

[1]Annamalai I, Chandramohan G, Srinivasa Prasad ND, Fernando E, Sujith S. Rapidly progressive glomerulonephritis due to anti‐glomerular basement membrane disease accompanied by IgA nephropathy: An unusual association. Saudi J Kidney Dis Transplant Off Publ Saudi Cent Organ Transplant Saudi Arab. diciembre de 2017;28(6):1404‐7.

[2]Deshpande NS, Tewari R, Badwal S, Mendonca S, Bharadwaj R. Evaluation of cases of membranoproliferative glomerulonephritis according to newer classification: A retrospective record‐based study. Med J Armed Forces India. julio de 2018;74(3):264‐7.

[3]Guo H, Wang B, Li H, Ling L, Niu J, Gu Y. Glucagon‐like peptide‐1 analog prevents obesity‐related glomerulopathy by inhibiting excessive autophagy in podocytes. Am J Physiol Renal Physiol. 01 de 2018;314(2):F181‐9.

[4]Park JM, Lee H, Song S, et al. Primary Glomerulonephritis with Unique C4d Deposition and Concurrent Non‐infectious Intermediate Uveitis: a Case Report and Literature Review. J Korean Med Sci. 30 de abril de 2018;33(18):e136.

[5]de Kort H, Willicombe M, Brookes P, et al. Peritubular Capillary Basement Membrane Multilayering in Renal Allograft Biopsies of Patients With De Novo Donor‐Specific Antibodies. Transplantation. abril de 2016;100(4):889‐97.

[6]Sethi S, Vrana JA, Fervenza FC, et al. Characterization of C3 in C3 glomerulopathy. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc‐ Eur Ren Assoc. 01 de 2017;32(3):459‐65.

[7]Malvar A, Davila P, Ferrari M, et al. Podocyte infolding glomerulopathy; report of the first case in Latin America and review of the literature. Nefrol Publicacion Of Soc Espanola Nefrol. 14 de enero de 2020;

[8]Pirozzi N, Stoppacciaro A, Menè P. Dominant C3 glomerulopathy: new roles for an old actor in renal pathology. J Nephrol. 2018;31(4):503‐10.

[9]García-Curdi F, Lois-Ortega Y, Gonzales-Sejas AG, Alfonso-Collado JI, Fumanal-Senz L, Vallés-Varela H. Enfermedad relacionada con IgG4 con afectación exclusiva nasosinusal: presentación de un caso clínico y revisión de la literatura. Rev Esp Patol. abril de 2019;52(2):125-9.

[10] Arapović A, Vukojević K, Filipović N, et al. Epidemiology of 10‐year paediatric renal biopsies in the region of southern Croatia. BMC Nephrol. diciembre de 2020;21(1):1‐12.

[11] Hashmi AA, Hussain Z, Edhi MM, Mumtaz S, Faridi N, Khan M. Insight to changing morphologic patterns of glomerulopathy in adult Pakistani patients: an institutional perspective. BMC Res Notes. 8 de febrero de 2016;9:73.

[12] Fukunaga M, Nagahama K, Aoki M, et al. Membranous Nephropathy‐ Like Apolipoprotein E Deposition Disease with Apolipoprotein E Toyonaka (Ser197Cys) and a Homozygous Apolipoprotein E2/2. Case Rep Nephrol Dial. abril de 2018;8(1):45-55.

[13] Pizzo HP, Haas M, Puliyanda D. Collagen type III glomerulopathy. Kidney Int. junio de 2018;93(6):1490.

[14] Dong J, Wei H, Han M, Guan Y, Wu Y, Li H. Collagen type III glomerulopathy: A case report and review of 20 cases. Exp Ther Med. octubre de 2015;10(4):1445-9.

[15] Stump M, Messingham KN, Fairley JA. Concurrent mucous membrane pemphigoid and membranous glomerulonephritis in a patient with autoantibodies targeting the 1080 region of collagen XVII. Br J Dermatol. 2019;181(4):835‐6.

[16] Roy S, Nalwa A, Keith J, Weck K, Singh H, Nickeleit V. Pseudolinear C4d deposits in a hereditary glomerulopathy caused by a rare NC1 collagen‐4‐alpha‐5 missense mutation: a «new disease entity»? Ultrastruct Pathol. 2019;43(4‐5):209‐15.

[17] Herrera GA. The value of ultrastructural evaluation in medical renal diseases. Ultrastruct Pathol. 2 de noviembre de 2019;43(6):225‐8.

[18] Hirashima H, Komiya T, Toriu N, et al. A case of nephrotic syndrome showing contemporary presence of apolipoprotein E2 homozygote glomerulopathy and membranous nephropathy-like findings modified by apolipoprotein E Toyonaka. Clin Nephrol Case Stud. 2018;6:45‐51.

[19] Kudose S, Santoriello D, Bomback AS, Stokes MB, D’Agati VD, Markowitz GS. Sensitivity and Specificity of Pathologic Findings to Diagnose Lupus Nephritis. Clin J Am Soc Nephrol CJASN. 7 de noviembre de 2019;14(11):1605‐15.

[20] Larsen CP, Sharma SG, Caza TN, et al. Serum amyloid P deposition is a sensitive and specific feature of membranous‐like glomerulopathy with masked IgG kappa deposits. Kidney Int. marzo de 2020;97(3):602‐8.

[21] Wong A, Cianciolo RE. Comparison of immunohistochemistry and immunofluorescence techniques using anti‐ lambda light chain antibodies for identification of immune complex deposits in canine renal biopsies. J Vet Diagn Investig Off Publ Am Assoc Vet Lab Diagn Inc. septiembre de 2018;30(5):721‐7.

[22] Bouatou Y, Kers J, Chevalier‐Florquin MSN, et al. Diagnostic accuracy of immunofluorescence versus immunoperoxidase staining to distinguish immune complex‐mediated glomerulonephritis and C3 dominant glomerulopathy. Histopathology. marzo de 2018;72(4):601‐8.

[23] Nasr SH, Fidler ME, Said SM. Paraffin Immunofluorescence: A Valuable Ancillary Technique in Renal Pathology. Kidney Int Rep. noviembre de 2018;3(6):1260‐6.

[24] Vessieres F, Cianciolo RE, Gkoka ZG, et al. Occurrence, management and outcome of immune‐complex glomerulonephritis in dogs with suspected glomerulopathy in the UK. J Small Anim Pract. noviembre de 2019;60(11):683‐90.

[25] Gong J, Zhan H, Li Y, Zhang W, Jin J, He Q. Krüppel‐like factor 4 ameliorates diabetic kidney disease by activating autophagy via the mTOR pathway. Mol Med Rep. octubre de 2019;20(4):3240‐8.

[26] Abd El hafez A, Hassan El‐Esawy B, Mamdouh Abdelaziz A, Alaa Saleh M. Factors affecting the distribution of glomerulonephropathies among adult Saudi patients: A single‐center, biopsy‐based clinico‐pathological study. IP Arch Cytol Histopathol Res. 28 de octubre de 2019;4(3):179‐86.

[27] Rosenberg AZ, Kopp JB. Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol CJASN. 7 de marzo de 2017;12(3):502‐17.

[28] Filippone EJ, McCue PA, Farber JL. Transplant glomerulopathy. Mod Pathol Off J U S Can Acad Pathol Inc. 2018;31(2):235‐52.

[29] Varshavsky VA, Grishina AN, Chebotareva NV, Gudkova EI. [The clinical and morphological characteristics of C1q glomerulopathy]. Arkh Patol. 2018;80(1):46‐51.

[30] Dinh A, Cuker A, Song W‐C, Hogan JJ. Monoclonal immunoglobulin–associated C3 glomerulopathy and thrombotic microangiopathy: A real association? J Onco‐Nephrol. 1 de febrero de 2019;3(1):3‐10.